CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer....
Phase 1
Barcelona, Catalunya, Spain and 12 other locations
This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell...
Phase 2
Barcelona, Spain and 49 other locations
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell...
Phase 2
Barcelona, Spain and 83 other locations
, HER3-DXd will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating mutation or squamous or non-squamous...
Phase 1
Barcelona, Spain and 21 other locations
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...
Phase 2
Barcelona, Spain and 33 other locations
in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with o...
Phase 3
Barcelona, Spain and 209 other locations
type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...
Phase 1, Phase 2
Barcelona, Spain and 123 other locations
cemiplimab or docetaxel in patients with advanced or metastasized non-small cell lung cancer (NSCLC) and...
Phase 1
Barcelona, Spain and 33 other locations
with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) wi...
Phase 2
Barcelona, Spain and 63 other locations
over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non...
Phase 1
Barcelona, Spain and 38 other locations
Clinical trials
Research sites
Resources
Legal